SCHEMBL1748980

SCHEMBL1748980

O[C]1CC=C(O)c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
MAPT P10636 4/20 0.41
HPGD P15428 3/20 0.41
MAPK1 P28482 2/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP3A4 P08684 2/20 0.41
PTPN22 Q9Y2R2 1/20 0.41
APAF1 O14727 1/20 0.33
TDP2 O95551 1/20 0.33
HSD17B10 Q99714 2/20 0.32
BCL2L1 Q07817 1/20 0.32
LMNA P02545 2/20 0.31
POLB P06746 2/20 0.31
TDP1 Q9NUW8 2/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
MCL1 Q07820 2/20 0.31
THRB P10828 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10028286 0.76 MAPT (0.43) ALDH1A1MAPTHPGDMAPK1KDM4E
SCHEMBL276263 0.75 HTR6 (0.40) ALDH1A1MAPTHPGDKDM4ECYP3A4
SCHEMBL13851701 0.67 PARP1 (0.40) ALDH1A1MAPTHPGDMAPK1KDM4E
SCHEMBL2566227 0.64 CES1 (0.50) ALDH1A1MAPTHPGDMAPK1KDM4E
SCHEMBL476571 0.64 HTR6 (0.36) CYP3A4LMNAMCL1SMN1; SMN2BCL2
SCHEMBL4436441 0.62 CES1 (0.43) HPGDL3MBTL1NPC1RAB9AMAOA
SCHEMBL1941287 0.62 ALDH1A1 (0.40) ALDH1A1MAPTHPGDMAPK1KDM4E
SCHEMBL28347434 0.62 ALDH1A1 (0.50) ALDH1A1MAPTHPGDMAPK1KDM4E
SCHEMBL29554575 0.60 MEN1 (0.57) ALDH1A1MAPTHPGDMAPK1KDM4E
SCHEMBL342409 0.59 KDM4E (1.00) ALDH1A1MAPTHPGDMAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113329993-A Use of polyhydroxy aromatic compounds for treating fibrous substrates based on amino acids 迈图高新材料有限责任公司 2021-08-31 CN claimed
US-20200163850-A1 USE OF POLYHYDROXYAROMATIC COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2020-05-28 US claimed
US-20080058435-A1 Halogen-Fere Flame-Retarded Polymer Foams BASF AKTIENGESELLSCHAFT (DE) 2008-03-06 US claimed
EP-1791896-B1 HALOGEN-FREE FLAME-RETARDED POLYMER FOAMS BASF AG (DE) 2008-02-13 EP claimed
US-20080027023-A1 Antiproliferative Compositions Comprising Aryl Substituted Xylopyranoside Derivatives GLUCOGENE MEDICAL HFM AB (SE) 2008-01-31 US claimed
EP-1765363-A2 NEW COMPOSITIONS GLUCOGENE MEDICAL HFM AB (SE) 2007-03-28 EP claimed
WO-2006006933-A2 ANTIPROLIFERATIVE COMPOSITIONS COMPRISING ARYL SUBSTITUTED XYLOPYRANOSIDE DERIVATIVES GLUCOGENE MEDICAL HFM AB (SE) 2006-01-19 WO claimed
JP-2003520819-A 2003-07-08 JP claimed
US-20030092637-A1 Novel compounds XYLOGEN AB (SE) 2003-05-15 US claimed
EP-1251859-A1 NOVEL COMPOUNDS Xylogen AB (SE) 2002-10-30 EP claimed
WO-2001054702-A1 NOVEL COMPOUNDS XYLOGEN AB (SE) 2001-08-02 WO claimed
CN-113329993-A Use of polyhydroxy aromatic compounds for treating fibrous substrates based on amino acids 迈图高新材料有限责任公司 2021-08-31 CN disclosed
US-20200163850-A1 USE OF POLYHYDROXYAROMATIC COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2020-05-28 US disclosed
US-7968591-B2 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use in medicaments GRUENENTHAL GMBH (DE) 2011-06-28 US disclosed
US-20090137573-A1 1,3-Disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their Use in Medicaments GRUENENTHAL GMBH (DE) 2009-05-28 US disclosed
EP-1791896-B1 HALOGEN-FREE FLAME-RETARDED POLYMER FOAMS BASF AG (DE) 2008-02-13 EP disclosed
EP-1791896-A1 HALOGEN-FREE FLAME-RETARDED POLYMER FOAMS BASF AKTIENGESELLSCHAFT (DE) 2007-06-06 EP disclosed
WO-2006027241-A1 HALOGEN-FREE FLAME-RETARDED POLYMER FOAMS BASF AKTIENGESELLSCHAFT (DE) 2006-03-16 WO disclosed
US-20030092637-A1 Novel compounds XYLOGEN AB (SE) 2003-05-15 US disclosed
US-4599397-A MELT-MOLDABLE MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) 1986-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092637-A1 Novel compounds ENTPD5, G6PD, G6PC1 ALDH1A1 986/4885MAPT 2389/4885HPGD 431/4885
US-20090137573-A1 1,3-Disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their Use in Medicaments OPRL1, TPH1, OPRK1 ALDH1A1 2168/4885MAPT 1404/4885HPGD 936/4885
US-20080027023-A1 Antiproliferative Compositions Comprising Aryl Substituted Xylopyranoside Derivatives UGGT1, B3GAT3, MKI67 ALDH1A1 1972/4885MAPT 4677/4885HPGD 1109/4885
US-20200163850-A1 USE OF POLYHYDROXYAROMATIC COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES PAH, CUTA, ASPH ALDH1A1 867/4885MAPT 676/4885HPGD 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.